£3m fund to help recover primary care backlogs

Commissioners can request immediate support for GPs to help mitigate risks in long-term conditions management

Support overburdened practices with digital ACR testing

Under current circumstances, thousands of patients at increased cardiovascular risk aren’t completing vital annual health checks like the ACR kidney health urine test for people with diabetes – and the new NHS Operational Planning Guidance is urging systems to respond with a recovery plan.

£3m funding is available now to subsidise digital testing for patients, helping to ensure these risks continue to be mitigated. The service takes less than an hour to set-up with GP practices, then the Healthy.io team will work on closing the backlogs, allowing GPs to continue with everything else.

This nationally significant programme, announced by the Department of Health and Social Care, is commissioned for delivery by Healthy.io in partnership with NHSx, the NHS Accelerated Access Collaborative and the National Institute for Health Research.

100,000 untested at-risk patients have now returned a test using Minuteful Kidney digital testing, in CCGs which are already using this funded support as a way of maintaining safe infrastructure despite additional current pressures.

Across the country, almost 2m people have still not completed an ACR test as part of their annual diabetes review, increasing the likelihood of heart attacks, heart failure, kidney failure, strokes and unplanned hospital admissions.

Dr Raj Thakkar testimonial video

Key benefits

How it works
Reach vulnerable patients who have not tested in the last 12 months by allowing them to test digitally when it’s most convenient.


Test kits can be used directly by untested patients who are identified through a simple search in SystmOne or EMIS


Patients test digitally using our test kit with help from our virtual nurse, Emily, who guides them throughout the entire exam


Results are analysed and uploaded to SystmOne or EMIS workflows in real time so GPs can access them directly

Retest icon


Abnormal results are immediately flagged and patients are encouraged to take another test to confirm results

Digital clinical-grade testing

Minuteful Kidney is helping to make digital testing the new normal, in line with the new NHS Operational Planning Guidance. Commissioners are now exploiting the potential of digital technologies to transform the delivery of care and patient outcomes

Digital testing uses the same point of care dipsticks as lab testing and generates equivalent results.  It measures semi quantitative analysis of microalbumin (10 – 150 mg/L), creatinine (10 – 300mg/dL) and albumin to creatinine ratio (mg/g).

Results are expressed as ACR normal (<30mg/g), ACR abnormal (30-300mg/g) or ACR high abnormal (>300mg/g).

The product is CE marked, GDPR compliant, and follows industry standards for privacy and safety.

What patients say

found the test 'easy' or 'very
easy' to use

96% icon

preferred testing digitally
vs. testing at the clinic

would recommend this service
to a friend

Get funding now

Securing support is quick and simple – just complete this request form and you will receive an immediate response to discuss next steps. This NHS England programme provides funding to match any investment into digital ACR testing made by local health systems. £3m remains for deployments which will support primary care recovery in the last quarter of 21/22 and the NHS funds are directly available through Healthy.io, the commissioned providers of the digital testing service.

By providing this information, you consent to receive relevant content from Healthy.io. (You may opt out at any point.) For more information, visit our Privacy Policy.

By providing this information, you consent to receive relevant content from Healthy.io. For more information, visit our Privacy Policy.
  1. Judith Shore, Michelle Green, Andrew Hardy & Deborah Livesey (2019): The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2019.1650024